Santen Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	287,994	300,004	301,965	279,037	266,257	249,605
Revenue Growth (YoY)	-4.61%	-0.65%	8.22%	4.80%	6.67%	3.33%
Cost of Revenue	123,949	128,977	123,256	112,950	109,671	98,221
Gross Profit	164,045	171,027	178,709	166,087	156,586	151,384
Selling, General & Admin	87,349	83,299	86,880	134,072	120,610	113,586
Research & Development	25,502	24,103	25,416	-	-	-
Other Operating Expenses	65	1,638	-282	-3,285	101	-15,710
Operating Expenses	121,741	122,732	126,524	130,787	120,711	97,876
Operating Income	42,304	48,295	52,185	35,300	35,875	53,508
Interest Expense	-2,882	-1,083	-831	-476	-249	-159
Interest & Investment Income	3,912	1,623	1,262	1,086	1,063	928
Earnings From Equity Investments	-685	-685	-7,575	-2,362	-1,604	-358
Currency Exchange Gain (Loss)	-	1,651	-121	-663	-959	-910
Other Non Operating Income (Expenses)	1	15	-198	-118	371	-120
EBT Excluding Unusual Items	42,650	49,816	44,722	32,767	34,497	52,889
Merger & Restructuring Charges	-1,100	-	-5,829	-3,225	-	-
Gain (Loss) on Sale of Investments	-	-708	-1,046	-228	800	-119
Gain (Loss) on Sale of Assets	-	-286	738	-554	412	-102
Asset Writedown	-1,302	-1,302	-7,547	-34,508	245	-40,250
Legal Settlements	-	-	-410	-51	-338	-
Other Unusual Items	-	-39	-755	-	-	-
Pretax Income	40,248	47,481	29,873	-5,799	35,616	12,418
Income Tax Expense	9,744	11,628	3,171	9,184	8,427	5,773
Earnings From Continuing Operations	30,504	35,853	26,702	-14,983	27,189	6,645
Minority Interest in Earnings	103	403	-60	35	29	185
Net Income	30,607	36,256	26,642	-14,948	27,218	6,830
Preferred Dividends & Other Adjustments	9	9	8	7	6	4
Net Income to Common	30,598	36,247	26,634	-14,955	27,212	6,826
Net Income Growth	11.32%	36.09%	-	-	298.51%	-71.08%
Shares Outstanding (Basic)	333	349	367	387	400	399
Shares Outstanding (Diluted)	333	350	368	387	400	400
Shares Change (YoY)	-6.20%	-5.01%	-4.98%	-3.26%	0.02%	0.03%
EPS (Basic)	92.02	103.98	72.59	-38.60	68.07	17.09
EPS (Diluted)	91.84	103.68	72.37	-38.60	67.97	17.06
EPS Growth	18.68%	43.26%	-	-	298.44%	-71.09%
Free Cash Flow	35,531	54,266	63,330	19,870	28,699	34,669
Free Cash Flow Per Share	106.62	155.18	172.03	51.29	71.67	86.59
Dividend Per Share	38.000	36.000	33.000	32.000	32.000	28.000
Dividend Growth	11.77%	9.09%	3.13%	-	14.29%	3.70%
Gross Margin	56.96%	57.01%	59.18%	59.52%	58.81%	60.65%
Operating Margin	14.69%	16.10%	17.28%	12.65%	13.47%	21.44%
Profit Margin	10.63%	12.08%	8.82%	-5.36%	10.22%	2.73%
Free Cash Flow Margin	12.34%	18.09%	20.97%	7.12%	10.78%	13.89%
EBITDA	60,507	66,243	70,363	52,549	52,930	70,276
EBITDA Margin	21.01%	22.08%	23.30%	18.83%	19.88%	28.16%
D&A For EBITDA	18,203	17,948	18,178	17,249	17,055	16,768
EBIT	42,304	48,295	52,185	35,300	35,875	53,508
EBIT Margin	14.69%	16.10%	17.28%	12.65%	13.47%	21.44%
Effective Tax Rate	24.21%	24.49%	10.62%	-	23.66%	46.49%
Advertising Expenses	-	13,310	18,278	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.